AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22472580 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 149
Study 22472580 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study 20553679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose leuprolide acetate administered subcutaneously at 4- to 5-day intervals up to 1 year
Number of subjects: 7
Study 20553679 — intervention group
Group type: EXPERIMENTAL
Intervention: Single GnRH-agonist injection
Number of subjects: 7
Study 20553679 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of GnRH-agonist
Number of subjects: 7
Study 18295023 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combined immunosuppression (infliximab 5 mg/kg at weeks 0, 2, and 6, plus azathioprine)
Number of subjects: 133
Study 18295023 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (corticosteroids followed by azathioprine and infliximab)
Number of subjects: 133
Study 18295023 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combined immunosuppression
Number of subjects: 133
Study 18295023 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 133
Study 16945127 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practitioners (combined yoga practices)
Number of subjects: 0
Study 16945127 — intervention group
Group type: COMPARATOR
Intervention: Non-yoga group (control)
Number of subjects: 0
Study 14636490 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic analysis of the SomnoStar 4100 system
Number of subjects: 28
Study 14636490 — intervention group
Group type: COMPARATOR
Intervention: Manual analysis (considered the gold standard)
Number of subjects: 28
Study 11087536 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple polyphenols (APP)
Number of subjects: 0
Study 11087536 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple condensed tannins (ACT)
Number of subjects: 0
Study 11087536 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple polyphenols (APP) and ACT
Number of subjects: 0
Study 9339157 — intervention group
Group type: EXPERIMENTAL
Intervention: One-half-inch shoe-lift applied to the contralateral, nonimmobilized shoe
Number of subjects: 8
Study 9339157 — intervention group
Group type: EXPERIMENTAL
Intervention: One-inch shoe-lift applied to the contralateral, nonimmobilized shoe
Number of subjects: 8
Study 9339157 — intervention group
Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 8
Study 9339157 — intervention group
Group type: COMPARATOR
Intervention: Knee immobilized
Number of subjects: 8
Study 8458247 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin plus clavulanic acid
Number of subjects: 164
Study 8458247 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime plus metronidazole
Number of subjects: 164
Study 3513319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednimustine
Number of subjects: 0
Study 3513319 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study 30013325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1390
Study 30013325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 1390
Study 30013325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (serious stroke subgroup, NIHSS >12)
Number of subjects: 1390
Study 30013325 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1390
Study 26671202 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated fractional skin microneedling (0.5 mm depth) followed by application of topical anesthetic cream (Lidocaine 2.5% + Prilocaine 2.5%)
Number of subjects: 15
Study 26671202 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia alone
Number of subjects: 15
Study 24376248 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound (MSUS) assessment
Number of subjects: 53
Study 22676346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 40
Study 22676346 — intervention group
Group type: COMPARATOR
Intervention: Visual Inspection
Number of subjects: 40
Study 20346190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-free diet
Number of subjects: 0
Study 20346190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-supplemented diet (14 g/l)
Number of subjects: 0
Study 20346190 — intervention group
Group type: COMPARATOR
Intervention: Baseline normal diets
Number of subjects: 0
Study 20346190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-supplemented diet
Number of subjects: 0
Study 18383654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (7 screening mammograms)
Number of subjects: 160000
Study 18383654 — intervention group
Group type: COMPARATOR
Intervention: Mammographic screening
Number of subjects: 160000
Study 15213095 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE consolidation therapy (idarubicin 9 mg/m2 x 3; cytarabine 3 g/m2 twice a day on days 1, 3, 5, 7; etoposide 75 mg/m2 x 7)
Number of subjects: 202
Study 15213095 — intervention group
Group type: COMPARATOR
Intervention: IcE consolidation therapy (cytarabine 100 mg/m2 daily x 5, idarubicin x 2, etoposide x 5)
Number of subjects: 202
Study 12094184 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training for 3 months followed by home-based training for 9 months
Number of subjects: 181
Study 12094184 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 181
Study 12094184 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181
Study 10028221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participation
Number of subjects: 667
Study 10028221 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment attrition
Number of subjects: 667
Study 7726307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine followed by exposure in vivo
Number of subjects: 96
Study 7726307 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological panic management followed by exposure in vivo
Number of subjects: 96
Study 7726307 — intervention group
Group type: COMPARATOR
Intervention: Exposure in vivo alone
Number of subjects: 96
Study 7726307 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by exposure in vivo
Number of subjects: 96
Study 1827621 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (0.6 mg/kg total body weight)
Number of subjects: 12
Study 6119098 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 7.5 mg
Number of subjects: 15
Study 6119098 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 30 mg
Number of subjects: 15
Study 6119098 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 45 mg
Number of subjects: 15
Study 6119098 — intervention group
Group type: COMPARATOR
Intervention: Quazepam 0 mg (placebo)
Number of subjects: 15
Study 31004339 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous muscle-derived cell (MDC) injection
Number of subjects: 20
Study 27765876 — intervention group
Group type: EXPERIMENTAL
Intervention: Home gardening participation
Number of subjects: 8500
Study 26113648 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 g of free essential amino acids (EAA) with high leucine levels
Number of subjects: 24
Study 26113648 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid mixture containing both EAA and non-EAA as present in whey protein
Number of subjects: 24
Study 23261050 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of intranasal live attenuated influenza vaccine (SA-LAIV)
Number of subjects: 4561
Study 23261050 — intervention group
Group type: COMPARATOR
Intervention: Health care provider administration of intranasal live attenuated influenza vaccine (HCP-LAIV)
Number of subjects: 4561
Study 21279450 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for in-pharmacy vaccination services
Number of subjects: 437
Study 21279450 — intervention group
Group type: COMPARATOR
Intervention: Neighborhood characteristics (high percent of minority residents)
Number of subjects: 437
Study 21279450 — intervention group
Group type: COMPARATOR
Intervention: Neighborhood characteristics (high percent of foreign-born residents)
Number of subjects: 437
Study 18802735 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-irradiation
Number of subjects: 190
Study 18802735 — intervention group
Group type: COMPARATOR
Intervention: Control (no neoadjuvant therapy)
Number of subjects: 190
Study 18802735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study 16452054 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid loading (ammonium chloride)
Number of subjects: 24
Study 14646682 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 28
Study 14646682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 28
Study 14646682 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 28
Study 14646682 — intervention group
Group type: COMPARATOR
Intervention: Comparison among treatment groups
Number of subjects: 28
Study 11074193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) at low stimulation (stimulation detection)
Number of subjects: 11
Study 11074193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) at high stimulation (maximum tolerability, maximum 1.75 mA)
Number of subjects: 11
Study 11074193 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 11
Study 8985623 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 6
Study 8985623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg)
Number of subjects: 6
Study 8985623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1280910 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for lateral epicondylitis
Number of subjects: 23
Study 1280910 — intervention group
Group type: COMPARATOR
Intervention: Cadaveric control specimens
Number of subjects: 23
Study 3926808 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5-0.75 micrograms/day)
Number of subjects: 56
Study 3926808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 3926808 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 56
Study 30151895 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ml of daily olive oil supplementation per rooster (Group 3)
Number of subjects: 3
Study 30151895 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ml of daily olive oil supplementation per rooster (Group 2)
Number of subjects: 3
Study 30151895 — intervention group
Group type: COMPARATOR
Intervention: Standard diet without olive oil supplementation (Group 1)
Number of subjects: 3
Study 27380342 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 90
Study 27380342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 24739333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (5.0 μg/kg)
Number of subjects: 10
Study 24739333 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 22462549 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy.me (web-based personally controlled health management system)
Number of subjects: 600
Study 22462549 — intervention group
Group type: COMPARATOR
Intervention: 6-month waitlist (control group)
Number of subjects: 600
Study 20147689 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 188
Study 20147689 — intervention group
Group type: COMPARATOR
Intervention: Traditional field outreach
Number of subjects: 188
Study 17521604 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Focused Attention (SFA) condition
Number of subjects: 44
Study 17521604 — intervention group
Group type: COMPARATOR
Intervention: Task-Focused Attention (TFA) condition
Number of subjects: 44
Study 16126314 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 16
Study 16126314 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 16
Study 12171451 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (nutrition intervention)
Number of subjects: 98
Study 12171451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 10616997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg orally per day, started 3 weeks preoperatively)
Number of subjects: 30
Study 10616997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7488409 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 1000 mg daily
Number of subjects: 94
Study 7488409 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 500 mg daily
Number of subjects: 94
Study 7488409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin assay
Number of subjects: 94
Study 7488409 — intervention group
Group type: EXPERIMENTAL
Intervention: Five tumour marker assays
Number of subjects: 94
Study 2301519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 50 mg
Number of subjects: 180
Study 2301519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 100 mg
Number of subjects: 180
Study 2301519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 200 mg
Number of subjects: 180
Study 2301519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 400 mg
Number of subjects: 180
Study 2301519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU‐486) 600 mg
Number of subjects: 180
Study 2301519 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (RU‐486) 0 mg
Number of subjects: 180
Study 6163362 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic biofeedback
Number of subjects: 20
Study 6163362 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 20
Study 31365099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (30 μg/d)
Number of subjects: 913
Study 31365099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 μg/d)
Number of subjects: 913
Study 31365099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 913
Study 28087235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand ventilation
Number of subjects: 36
Study 28087235 — intervention group
Group type: COMPARATOR
Intervention: Machine ventilation
Number of subjects: 36
Study 25877442 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Lidose hard capsule
Number of subjects: 24
Study 25877442 — intervention group
Group type: COMPARATOR
Intervention: 145 mg nanoparticle tablet
Number of subjects: 24
Study 24408766 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV 2 mm [45 Hz and 2 mm]
Number of subjects: 8
Study 24408766 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV 4 mm [45 Hz and 4 mm]
Number of subjects: 8
Study 24408766 — intervention group
Group type: COMPARATOR
Intervention: No WBV
Number of subjects: 8
Study 22999135 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex nondrug intervention including actively approaching counseling and caregiver support groups
Number of subjects: 390
Study 22999135 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 390
Study 19152681 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility fraction
Number of subjects: 148
Study 19152681 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolment fraction
Number of subjects: 148
Study 19152681 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to screen (NNS)
Number of subjects: 148
Study 17223857 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (10-1400 mg)
Number of subjects: 27
Study 17223857 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (1400 mg)
Number of subjects: 27
Study 17223857 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (150 mg)
Number of subjects: 27
Study 17223857 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (600 mg)
Number of subjects: 27
Study 17223857 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (150 mg) with high-fat meal
Number of subjects: 27
Study 17223857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 14707412 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g L-arginine infusion
Number of subjects: 55
Study 11730275 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting period (R) after a protein meal (1.2 g/kg b.w. of protein)
Number of subjects: 13
Study 11730275 — intervention group
Group type: COMPARATOR
Intervention: Behavioural stress period (S) after a protein meal (1.2 g/kg b.w. of protein)
Number of subjects: 13
Study 9570827 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric dialysis method for determining free 1,25(OH)2D
Number of subjects: 23
Study 9570827 — intervention group
Group type: COMPARATOR
Intervention: Centrifugal ultrafiltration method for determining free 1,25(OH)2D
Number of subjects: 23
Study 8053797 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program based on eye‐head coupling (RG)
Number of subjects: 60
Study 8053797 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 1827271 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 4 mg/kg as a single intravenous dose (regimen A)
Number of subjects: 65
Study 1827271 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 3 mg/kg in two doses (regimen B)
Number of subjects: 65
Study 1827271 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (single dose)
Number of subjects: 65
Study 1827271 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (divided dose)
Number of subjects: 65
Study 1827271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 65
Study 31390660 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg twice a day)
Number of subjects: 24
Study 31390660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31050359 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPL/DBBM/CM
Number of subjects: 30
Study 31050359 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM/CM
Number of subjects: 30
Study 31050359 — intervention group
Group type: COMPARATOR
Intervention: SH
Number of subjects: 30
Study 28409564 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 152
Study 28409564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 26546647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (system change innovation to connect patients to primary care)
Number of subjects: 140
Study 23523988 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine plus brief alcohol intervention (BI)
Number of subjects: 83
Study 23523988 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine alone
Number of subjects: 83
Study 21084429 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel (GD)
Number of subjects: 475
Study 21084429 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus docetaxel (CD)
Number of subjects: 475
Study 21084429 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover groups (GD→C or CD→G)
Number of subjects: 475
Study 21084429 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 475
Study 19247023 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (laparoscopic adrenalectomy)
Number of subjects: 45
Study 19247023 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 45
Study 16899425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaric acid esters (FAE's, Fumaderm) at a maximum dose of 120 mg dimethylfumarate per day for six months
Number of subjects: 10
Study 16186995 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with 0.57 g/kg glutamine‐dipeptide
Number of subjects: 32
Study 16186995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12540411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-carbohydrate (LF-HC) diet
Number of subjects: 36
Study 12540411 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat low-carbohydrate (HF-LC) diet
Number of subjects: 36
Study 12540411 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet
Number of subjects: 36
Study 12540411 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study 9894690 — intervention group
Group type: EXPERIMENTAL
Intervention: Curvature discrimination along the middle finger orientation
Number of subjects: 0
Study 9894690 — intervention group
Group type: COMPARATOR
Intervention: Curvature discrimination across the middle finger orientation
Number of subjects: 0
Study 9894690 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of surface shape on curvature perception
Number of subjects: 0
Study 9894690 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination orientation influence
Number of subjects: 0
Study 7485933 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 150 micrograms/kg (Group A)
Number of subjects: 213
Study 7485933 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 75 micrograms/kg (Group B)
Number of subjects: 213
Study 7485933 — intervention group
Group type: COMPARATOR
Intervention: droperidol 75 micrograms/kg (Group C)
Number of subjects: 213
Study 2386281 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (n = 20)
Number of subjects: 60
Study 2386281 — intervention group
Group type: COMPARATOR
Intervention: No artificial humidification (n = 20)
Number of subjects: 60
Study 2386281 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier (n = 20)
Number of subjects: 60
Study 7353349 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 6
Study 7353349 — intervention group
Group type: COMPARATOR
Intervention: Inactivity
Number of subjects: 6
Study 7353349 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized physical activity
Number of subjects: 6